Abstract 203P
Background
Esophageal squamous cell carcinoma (ESCC) is the main subtype of esophageal cancer in China. We conducted a prospective clinical trial of preoperative Durvalumab combined chemotherapy in patients with locally advanced ESCC.
Methods
Clinical resectable IIB-IVA ESCC patients were enrolled in the study. Patient received neoadjuvant Durvalumab 750mg combined chemotherapy (docetaxel 75mg/m2 plus cisplatin 75mg/m2 or carboplatin area under curve 4-5) every 3 weeks for 4 cycles before surgery. The primary endpoint was the pathological complete response rate (pCR) and the radical resection rate (R0).
Results
26 eligible patients were enrolled in the study and all completed four cycles of neoadjuvant therapy. The objective response rate is 80.8%, and the disease control rate was 100%. Among the 22 resectable tumor patients, 20 received McKeown MIE, and the other 2 patients who achieved response (1 PR and 1 CR) refused surgery due to concerns about complications. 20 patients underwent esophagectomy within 33-60 days (median 47 days) after neoadjuvant therapy, and 19 patients underwent radical resection with a R0 resection rate of 95%. pCR (ypT0N0) was observed in 3 patients (15.8%). 2 patients (10.5%) achieved complete remission of the primary tumor (ypT0N1). 1 patient (5.3%) had an American Society of Pathologists (CAP) score of 1, 7 patients (36.8%) had a CAP score of 2, and 8 patients (6/19, 31.6%) had a CAP score of 3. Most treatment-related AEs (TRAEs) were grade 1 or 2. 8 cases (30.8%), 13 cases (50%), and 1 case (3.8%) developed leukopenia, decreased neutrophil count, and dermatitis, respectively ¾ Level TRAE. In terms of surgical complications, 2 patients had anastomotic leakage (10%), and 1 patient had recurrent laryngeal nerve injury (5%).
Conclusions
The combination of neoadjuvant Durvalumab chemotherapy has achieved satisfactory initial efficacy and safety results in locally advanced ESCC. Neoadjuvant immunotherapy does not increase perioperative complications and can achieve higher pathological remission rates, which may lead to better PFS and OS in the future. This study is currently the first clinical trial to use PD-L1 inhibitors in the treatment of esophageal squamous cell carcinoma.
Clinical trial identification
NCT04568200.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
623P - Advances in methylation analysis of liquid biopsy in early cancer detection of colorectal and lung cancer
Presenter: Sam Martin
Session: Poster Display
Resources:
Abstract
624P - Pan-cancer single-cell isoform atlas: Unraveling isoform dynamics in cancer immunotherapy
Presenter: Lu Pan
Session: Poster Display
Resources:
Abstract
625P - The association of tumor marker concentration and air pollution in cancer survivors and the general population
Presenter: Kyae Hyung Kim
Session: Poster Display
Resources:
Abstract
626P - Percentage of cancer patients undergoing adjusted targeted therapy after ctDNA testing: Insights from a tertiary hospital experience
Presenter: Jisook Yim
Session: Poster Display
Resources:
Abstract
627P - Racial disparities in synchronous and metachronous colorectal and prostate cancer: SEER based study 2000-2020
Presenter: Taha Nagib
Session: Poster Display
Resources:
Abstract